{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:39:38Z","timestamp":1793734778813,"version":"4.6.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"6","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Adult T-cell leukemia\/lymphoma (ATL) is triggered by infection with human T-cell lymphotropic virus-1 (HTLV-1). Here, we describe the reprogramming of pyrimidine biosynthesis in both normal T cells and ATL cells through regulation of uridine-cytidine kinase 2 (UCK2), which supports vigorous proliferation. UCK2 catalyzes the monophosphorylation of cytidine\/uridine and their analogues during pyrimidine biosynthesis and drug metabolism. We found that UCK2 was overexpressed aberrantly in HTLV-1\u2013infected T cells but not in normal T cells. T-cell activation via T-cell receptor (TCR) signaling induced expression of UCK2 in normal T cells. Somatic alterations and epigenetic modifications in ATL cells activate TCR signaling. Therefore, we believe that expression of UCK2 in HTLV-1\u2013infected cells is induced by dysregulated TCR signaling. Recently, we established azacitidine-resistant (AZA-R) cells showing absent expression of UCK2. AZA-R cells proliferated normally in\u00a0vitro, whereas UCK2 knockdown inhibited ATL cell growth. Although uridine and cytidine accumulated in AZA-R cells, possibly because of dysfunction of pyrimidine salvage biosynthesis induced by loss of UCK2 expression, the amount of UTP and CTP was almost the same as in parental cells. Furthermore, AZA-R cells were more susceptible to an inhibitor of dihydroorotic acid dehydrogenase, which performs the rate-limiting enzyme of de novo pyrimidine nucleotide biosynthesis, and more resistant to dipyridamole, an inhibitor of pyrimidine salvage biosynthesis, suggesting that AZA-R cells adapt to UCK2 loss by increasing de novo pyrimidine nucleotide biosynthesis. Taken together, the data suggest that fine-tuning pyrimidine biosynthesis supports vigorous cell proliferation of both normal T cells and ATL cells.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011131","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T21:08:56Z","timestamp":1704748136000},"page":"1345-1358","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4166-4781","authenticated-orcid":false,"given":"Tatsuro","family":"Watanabe","sequence":"first","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kurahashi","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan"},{"name":"2OHARA Pharmaceutical Co, Ltd, Shiga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9476-3161","authenticated-orcid":false,"given":"Kazunori","family":"Kawasoe","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan"},{"name":"3Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0712-0083","authenticated-orcid":false,"given":"Keisuke","family":"Kidoguchi","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan"},{"name":"3Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ureshino","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan"},{"name":"3Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7346-4864","authenticated-orcid":false,"given":"Kazuharu","family":"Kamachi","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan"},{"name":"3Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8375-3662","authenticated-orcid":false,"given":"Nao","family":"Yoshida-Sakai","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan"},{"name":"3Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Fukuda-Kurahashi","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan"},{"name":"2OHARA Pharmaceutical Co, Ltd, Shiga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0449-7830","authenticated-orcid":false,"given":"Hideaki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"4Department of Transfusion Medicine, Saga University Hospital, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-5206","authenticated-orcid":false,"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[{"name":"5Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaburo","family":"Sueoka","sequence":"additional","affiliation":[{"name":"6Department of Clinical Laboratory Medicine, Faculty of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan"},{"name":"3Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"issue":"11","key":"2024032514054736000_bib1","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"2024032514054736000_bib2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2016-09-692574","article-title":"Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells","volume":"129","author":"Watanabe","year":"2017","journal-title":"Blood"},{"key":"2024032514054736000_bib3","doi-asserted-by":"crossref","first-page":"957535","DOI":"10.3389\/fimmu.2022.957535","article-title":"Interplay between innate immunity and the viral oncoproteins Tax and HBZ in the pathogenesis and therapeutic response of HTLV-1 associated adult T cell leukemia","volume":"13","author":"El Hajj","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"2024032514054736000_bib4","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat Genet"},{"issue":"9","key":"2024032514054736000_bib5","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1111\/cas.13303","article-title":"Genetic alterations in adult T-cell leukemia\/lymphoma","volume":"108","author":"Kogure","year":"2017","journal-title":"Cancer Sci"},{"issue":"3","key":"2024032514054736000_bib6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3390\/v14030587","article-title":"Clonal selection and evolution of HTLV-1-infected cells driven by genetic and epigenetic alteration","volume":"14","author":"Yamagishi","year":"2022","journal-title":"Viruses"},{"issue":"21","key":"2024032514054736000_bib7","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.3390\/cancers13215542","article-title":"CCR4 as a therapeutic target for cancer immunotherapy","volume":"13","author":"Yoshie","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"2024032514054736000_bib8","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3324\/haematol.2010.028605","article-title":"Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia\/lymphoma as a target for epigenetic therapy","volume":"96","author":"Sasaki","year":"2011","journal-title":"Haematologica"},{"issue":"8","key":"2024032514054736000_bib9","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep"},{"issue":"10","key":"2024032514054736000_bib10","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm, phase 2 trial of valemetostat in relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2024032514054736000_bib11","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1158\/1078-0432.CCR-13-3169","article-title":"CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia\/lymphoma","volume":"20","author":"Kobayashi","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024032514054736000_bib12","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1111\/cas.14219","article-title":"CD4(+) CADM1(+) cell percentage predicts disease progression in HTLV-1 carriers and indolent adult T-cell leukemia\/lymphoma","volume":"110","author":"Makiyama","year":"2019","journal-title":"Cancer Sci"},{"issue":"6","key":"2024032514054736000_bib13","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/bloodadvances.2019001429","article-title":"Proteomic profiling of HTLV-1 carriers and ATL patients reveals sTNFR2 as a novel diagnostic biomarker for acute ATL","volume":"4","author":"Guerrero","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2024032514054736000_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood.2019003084","article-title":"Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100","volume":"136","author":"Watanabe","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2024032514054736000_bib15","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/ijc.33901","article-title":"Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism","volume":"150","author":"Yoshida-Sakai","year":"2022","journal-title":"Int J Cancer"},{"key":"2024032514054736000_bib16","doi-asserted-by":"crossref","first-page":"684961","DOI":"10.3389\/fonc.2021.684961","article-title":"Targeting pyrimidine metabolism in the era of precision cancer medicine","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"2024032514054736000_bib17","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.biopha.2018.10.200","article-title":"Involvement of the uridine cytidine kinase 2 enzyme in cancer cell death: a molecular crosstalk between the enzyme and cellular apoptosis induction","volume":"109","author":"Malami","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"2024032514054736000_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13148-016-0237-y","article-title":"A\u00a0clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers","volume":"8","author":"Diesch","year":"2016","journal-title":"Clin Epigenetics"},{"issue":"9","key":"2024032514054736000_bib19","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1111\/cas.14125","article-title":"Uridine-cytidine kinase 2 (UCK2): a potential diagnostic and prognostic biomarker for lung cancer","volume":"110","author":"Wu","year":"2019","journal-title":"Cancer Sci"},{"issue":"2","key":"2024032514054736000_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4048\/jbc.2017.20.2.132","article-title":"Overexpression of uridine-cytidine kinase 2 correlates with breast cancer progression and poor prognosis","volume":"20","author":"Shen","year":"2017","journal-title":"J\u00a0Breast Cancer"},{"issue":"4","key":"2024032514054736000_bib21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/mc.22954","article-title":"Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness","volume":"58","author":"Huang","year":"2019","journal-title":"Mol Carcinog"},{"issue":"12","key":"2024032514054736000_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41389-020-00287-7","article-title":"Non-metabolic role of UCK2 links EGFR-AKT pathway activation to metastasis enhancement in hepatocellular carcinoma","volume":"9","author":"Cai","year":"2020","journal-title":"Oncogenesis"},{"key":"2024032514054736000_bib23","first-page":"539748","article-title":"Comparative study of human hematopoietic cell engraftment into BALB\/c and C57BL\/6 strain of rag-2\/jak3 double-deficient mice","volume":"2011","author":"Ono","year":"2011","journal-title":"J\u00a0Biomed Biotechnol"},{"issue":"5843","key":"2024032514054736000_bib24","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/294770a0","article-title":"Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells","volume":"294","author":"Miyoshi","year":"1981","journal-title":"Nature"},{"issue":"1","key":"2024032514054736000_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ccr.2011.12.015","article-title":"Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers","volume":"21","author":"Yamagishi","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"2024032514054736000_bib26","first-page":"95","article-title":"Torin2 potentiates anticancer effects on adult T-cell leukemia\/lymphoma by inhibiting mammalian target of rapamycin","volume":"36","author":"Watanabe","year":"2016","journal-title":"Anticancer Res"},{"issue":"43","key":"2024032514054736000_bib27","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2024032514054736000_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"issue":"12","key":"2024032514054736000_bib29","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular Signatures Database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"issue":"6","key":"2024032514054736000_bib30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"issue":"1","key":"2024032514054736000_bib31","doi-asserted-by":"crossref","first-page":"13474","DOI":"10.1038\/s41598-021-92948-9","article-title":"De novo deoxyribonucleotide biosynthesis regulates cell growth and tumor progression in small-cell lung carcinoma","volume":"11","author":"Maruyama","year":"2021","journal-title":"Sci Rep"},{"key":"2024032514054736000_bib32","doi-asserted-by":"crossref","first-page":"3181759","DOI":"10.1155\/2018\/3181759","article-title":"Coenzyme Q10 prevents senescence and dysfunction caused by oxidative stress in vascular endothelial cells","volume":"2018","author":"Huo","year":"2018","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"2024032514054736000_bib33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2024032514054736000_bib34","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood-2004-09-3646","article-title":"Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia","volume":"106","author":"Watanabe","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2024032514054736000_bib35","doi-asserted-by":"crossref","first-page":"102494","DOI":"10.1016\/j.isci.2021.102494","article-title":"DHODH inhibition modulates glucose metabolism and circulating GDF15, and improves metabolic balance","volume":"24","author":"Zhang","year":"2021","journal-title":"iScience"},{"issue":"12","key":"2024032514054736000_bib36","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1074\/jbc.275.12.8375","article-title":"Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine","volume":"275","author":"Ward","year":"2000","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"2024032514054736000_bib37","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/mol.59.5.1181","article-title":"Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases","volume":"59","author":"Van Rompay","year":"2001","journal-title":"Mol Pharmacol"},{"key":"2024032514054736000_bib38","doi-asserted-by":"crossref","first-page":"840610","DOI":"10.3389\/fimmu.2022.840610","article-title":"T\u00a0cell metabolism in infection","volume":"13","author":"Wik","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"2024032514054736000_bib39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/cells11040739","article-title":"Re-discovery of pyrimidine salvage as target in cancer therapy","volume":"11","author":"Walter","year":"2022","journal-title":"Cells"},{"key":"2024032514054736000_bib40","doi-asserted-by":"crossref","first-page":"114176","DOI":"10.1016\/j.ejmech.2022.114176","article-title":"Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: current development and future perspectives","volume":"232","author":"Zhang","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"4","key":"2024032514054736000_bib41","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","article-title":"Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network","volume":"35","author":"Gu","year":"2021","journal-title":"Leukemia"},{"key":"2024032514054736000_bib42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-3-642-29423-5_9","article-title":"Targeting phosphodiesterases in anti-platelet therapy","volume":"210","author":"Rondina","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"2024032514054736000_bib43","doi-asserted-by":"crossref","first-page":"115376","DOI":"10.1016\/j.bcp.2022.115376","article-title":"Dipyridamole interacts with the N-terminal domain of HSP90 and antagonizes the function of the chaperone in multiple cancer cell lines","volume":"207","author":"Gao","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"18","key":"2024032514054736000_bib44","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1016\/j.bmcl.2019.08.010","article-title":"Discovery of small molecule inhibitors of human uridine-cytidine kinase 2 by high-throughput screening","volume":"29","author":"Okesli-Armlovich","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"21","key":"2024032514054736000_bib45","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1021\/acs.biochem.2c00451","article-title":"Structure-based prototyping of allosteric inhibitors of human uridine\/cytidine kinase 2 (UCK2)","volume":"61","author":"Mashayekh","year":"2022","journal-title":"Biochemistry"},{"issue":"3","key":"2024032514054736000_bib46","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10557-021-07224-9","article-title":"Why not dipyridamole: a review of current guidelines and re-evaluation of utility in the modern era","volume":"36","author":"Allahham","year":"2022","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/6\/1345\/2219088\/blooda_adv-2023-011131-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/6\/1345\/2219088\/blooda_adv-2023-011131-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T14:06:30Z","timestamp":1711375590000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/6\/1345\/506979\/Reprogramming-of-pyrimidine-nucleotide-metabolism"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011131","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,13]]}}}